Background In patients suff ering from upper gastrointestinal bleeding (UGIB), adequate visualization is essential during endoscopy. Prior to endoscopy, erythromycin administration has been shown to enhance visualization in these patients; however, guidelines have not fully adopted this practice. Th us, we performed a comprehensive, up-to-date meta-analysis on the issue of erythromycin administration in this patient population.
Introduction
Upper gastrointestinal bleeding (UGIB) is a medical condition that is associated with signifi cant morbidity and healthcare cost burden. Th e incidence and mortality of UGIB may range from 48-160 adult cases per 100,000 per year and 10-14%, respectively [1] . Th e estimated direct costs for management of UGIB in the USA are over 1 billion dollars (US) annually [2] . Endoscopic treatment may improve immediate and delayed clinical outcomes. But there is one global challenge of urgent esophagogastroduodenoscopy (EGD) and that is the presence of retained blood or other residual material in the stomach, which may interfere not only with endoscopic evaluation but also with both immediate and delayed outcome of UGIB management [3] . Various methods including gastric lavage may aff ect and reduce the interference of retained blood clot or other residual materials in emergent EGD but due to its own morbidity and time consumption, the outcomes were not satisfactory [4] .
On the other hand, erythromycin is a cost-eff ective, macrolide antibiotic which is a motilin receptor agonist [5] . It is also known to induce gastric motility that can translate into eff ective gastric emptying before emergent endoscopy. In multiple studies, it was shown that early administration of erythromycin before endoscopy in acute UGIB can have positive outcomes in the need for second-look endoscopy, endoscopic visualization, blood transfusions, hospital stay, procedure duration, and mortality [6] [7] [8] [9] . But the individual randomized trials did not have large number of subjects and there has been no recent meta-analysis that included all the trials examining both the clinical and economic outcomes of erythromycin administration before endoscopy for acute UGIB.
Th e aim of our study was to perform an up-to-date metaanalysis with all the available randomized clinical trials and evaluate the use of erythromycin administration prior to endoscopy for acute UGIB patients in regard to adequate visualization, need for second endoscopy, hospital length of stay, and need for blood transfusion.
Materials and methods

Literature search
A literature search was performed in November 2015 consisting of three well-known search strategies. First, a search of popular databases, including Medline/PubMed, Scopus, CINAHL, and the Cochrane databases, was performed using erythromycin, endoscopy, and bleeding ("erythromycin" [ 
Data extraction
Data extraction was conducted by two independent reviewers (RR, MLB) from all included studies using a standardized data extraction sheet. Any disagreement among those two reviewers was settled by mutual agreement or involvement of a third party reviewer (DN).
Statistical analysis
Studies on adult patients with UGIB that compared erythromycin administration before endoscopy to no erythromycin or placebo were identifi ed and used in this metaanalysis. Data was collected for the following outcomes: gastric visualization, need for second-look endoscopy, units of blood transfused, length of endoscopy, length of hospital stay, and need for emergent surgery. Th e data was pooled, analyzed, and reported as odds ratio (OR), for dichotomous data, and mean diff erence (MD), for continuous data, using the Mantel-Haenszel (fi xed eff ect) model in outcomes with no heterogeneity and the DerSimonian and Laird (random eff ects) model in outcomes with signifi cant heterogeneity. Heterogeneity among pooled studies was calculated using the I 2 measure of inconsistency (signifi cant if P < 0.10 or I 2 > 50%). If heterogeneity was discovered, the random eff ects model was utilized as well as a sensitivity analysis performed by removing the least amount of studies necessary to reach non-signifi cant heterogeneity and comparing results to the original pooled data. Data was analyzed by using RevMan 5.3 (Review Manager, Version 5.3, Copenhagen: Th e Nordic Cochrane Centre, Th e Cochrane Collaboration, 2012). Publication bias was assessed using funnel plots.
Quality assessment of studies
Th e Cochrane's Collaboration Risk of Bias Tool was used to assess the quality of included studies [10] . In this tool, each outcome was given a GRADE (very low, low, moderate, or high) based on the quality of evidence. Th e parameters evaluated in each study were as follows: precision, consistency of results, eff ect magnitude, and potential bias (publication and other forms) [10] .
Results
Selection of studies
Aft er a comprehensive search, 229 potential articles were identifi ed (Fig. 1 ). Of these articles, based upon title and abstract, 20 studies were examined more closely. Aft er full text examination, eight studies met the inclusion criteria. Details of the included studies are found in Table 1 .
Quality assessment of studies
Th e quality of the studies included in this meta-analysis was extensively evaluated using Cochrane's Collaboration Risk of Bias Tool [10] . Details of quality assessment described in Table 2 .
Visualization of the gastric mucosa
Gastric visualization was evaluated in all eight included studies (n=598) [11] [12] [13] [14] [15] [16] [17] [18] (Fig. 2) . Heterogeneity was found at a signifi cant level (I 2 =64%, P<0.01). Sensitivity analysis was performed and aft er removing one study [15] and revealed similar results (OR 5.13; 95% CI: 2.66-9.87; P<0.01) with no signifi cant heterogeneity (I 2 =42%, P=0.11). Th e number needed to treat with erythromycin to optimize gastric visualization was four patients. Publication bias was non-signifi cant.
Need for second-look endoscopy
If adequate visualization of the mucosa is not apparent, a second-look endoscopy may be required. All eight studies evaluated the need a second endoscopy (n=598) [11] [12] [13] [14] [15] [16] [17] [18] . Second-look endoscopy was necessary in 45/298 (15.1%) in the erythromycin group and 77/300 (25.7%) in the no erythromycin group. Upon pooling of the data, the odds of needing a secondlook endoscopy was statistically reduced in the erythromycin group compared to no erythromycin group (OR 0.51; 95% CI: 0.34-0.77; P<0.01) (Fig. 3) . Heterogeneity (I 2 =24%, P=0.24) and publication bias were found to be non-signifi cant. Overall, the number of patients needed to treat with erythromycin to prevent a need for second-look endoscopy was nine patients.
Blood transfusion
Blood transfusion was reported in six of the studies (n=544) [11] [12] [13] [14] [15] 18] . Th is outcome was reported as mean number of packed red blood cells required for each patient with UGIB. Unlike meta-analyses in the past, the administration of erythromycin showed no statistically signifi cant diff erence to no erythromycin for amount of blood transfusions required (MD -1.06; 95% CI: -2.24-0.13; P=0.08); Table 3 . Th is result may be due to signifi cant heterogeneity (I 2 =89%, P<0.01). Upon sensitivity analysis of one study's removal [18] , no heterogeneity was identifi ed (I 2 =0%, P=0.85) and the results demonstrated that erythromycin administration decreased the amount of blood transfusions compared to no erythromycin (MD -0.41; 95% CI: -0.82 to -0.01; P=0.04). Publication bias was not apparent.
Length of hospital stay
Hospital stay was evaluated in fi ve studies (n=375) by mean number of days spent in the hospital [11] [12] [13] [14] 18] . Th e use of preprocedure erythromycin showed a statistically signifi cant odds of fewer days in the hospital stay (MD -1.75; 95% CI: -2.43 to -1.06, P<0.01) compared to the no erythromycin (Table 3) . Th e heterogeneity was found to be insignifi cant (I 2 =0%, P=0.55) and no publication bias observed.
Duration of procedure
Endoscopy duration, measured by mean minutes of the procedure, was assessed in fi ve studies (n=503) [11,13- Altraif et al 2011 [14] Ardakani et al 2013 [18] Carbonell et al 2006 [11] Coffin et al 2002 [12] Frossard et al 2002 [13] Habashi et al 2007 [17] Pateron et al 2011 [15] Rudzki et al 2006 [16] Total (95% Cl) Total events Heterogeneity: chi 2 = 9.22, df= 7 (P = 0.24); l 2 = 24% Test for overall effect: Z = 3.17 (P = 0.002) =0%, P=0.67) when three studies were removed [13, 14, 18] .
Need for emergent surgery
Th e need for emergent surgery was analyzed by two studies (n=146) [12, 13] . No diff erence was observed for the need for emergent surgery between those patients receiving preendoscopic erythromycin (4/70, 1.4%) compared to those not receiving erythromycin (4/76, 5.3%) (OR 1.11; 95% CI: 0.27-4.67; P=0.88) with no publication bias or signifi cant heterogeneity (Table 3) .
Discussion
UGIB is a life-threatening condition that requires prompt recognition and management. Erythromycin administration before endoscopy in patients with UGIB has been shown useful in many randomized controlled trials (RCTs) to help with visualization of gastric mucosa. However, guidelines have been slow to evolve.
In 2010, the international consensus recommendations by Barkun et al [1] were published and despite the fi ve published RCTs [11] [12] [13] 16, 17] and one meta-analysis [6] on the subject of erythromycin at time, the group recommended that promotility agents should not be routinely used prior to endoscopy in UGIB patients [1] . However, this recommendation included trials using erythromycin and metoclopramide which likely infl uenced the outcome consensus as metoclopramide seems to be less eff ective [19] . In 2011, two meta-analyses [7, 8] were published including only studies using erythromycin and discovered that the use of erythromycin prior to endoscopy increased the odds of adequate gastric visualization while decreasing the odds of a second-look endoscopy. Subsequently in 2011, two additional RCTs on the subject were published [14, 15] . Based on these new studies and metaanalyses, in 2012, the American Society for Gastrointestinal Endoscopy recommended the possibility of using a prokinetic agent prior to endoscopy in patients with high probability of fresh blood or clots in stomach but not for routine use [20] . Also, in 2012, the American College of Gastroenterology recommended pre-procedure erythromycin in UGIB patients should be considered for increasing diagnostic yield and decreasing need for second-look endoscopy [3] . However, this guideline stated that erythromycin did not consistently improve clinical outcomes [3] . In 2013, a meta-analysis of six studies (n=558) was repeated showing erythromycin administration signifi cantly improved gastric visualization while decreasing hospital stay, units of blood transfused, and need for a second endoscopy [9] . In 2013, another RCT was published with similar results to studies in the past [18] . In 2015, for the fi rst time, the European Society of Gastrointestinal Endoscopy strongly recommended erythromycin administration prior to endoscopy in patients with severe or ongoing UGIB based on high quality evidence [21] . Despite this recommendation, practice outside of Europe may not have evolved.
In 2016, this updated meta-analysis adds to the overall evidence that erythromycin before endoscopy in UGIB patients by including all RCTs to-date. Th is meta-analysis demonstrated increased odds of gastric visualization while decreasing the odds of second-look endoscopy and length of hospital stay. In this meta-analysis, the mean units of blood transfusions did not diff er as it has in past analyses. Th e likely reason is the signifi cant heterogeneity that was apparent when the most recent study [18] was included. If this study was eliminated, the result would be signifi cant without heterogeneity, suggesting that the mean units of blood transfused would likely be decreased with the use of pre-procedure erythromycin. Th is updated meta-analysis may infl uence parties outside of Europe to alter guidelines and practice.
However, despite including all the high quality RCTs published on the subject, this study has a few limitations. First, the doses of erythromycin varied among the studies, ranging from 125 mg to 250 mg. However, this eff ect on overall outcomes was likely insignifi cant given that erythromycin in low doses (70 mg) has been shown to accelerate gastric emptying [22] . Second, two of the four outcomes (gastric visualization and units of blood transfused) demonstrated signifi cant heterogeneity. Compensation for this eff ect was performed by using a random eff ects model and sensitivity analysis. On sensitivity analysis, gastric visualization demonstrated similar results; however, units of blood transfused did not, as mentioned earlier, which may have impacted this result. Th ird, three studies utilized nasogastric lavage in both arms [11, 15, 18] . Given both arms was subjected to the same treatment with and without erythromycin, impact on overall results should be minimal. Fourth, gastric visualization was determined adequate or inadequate based on the authors' discretion for each study. Th erefore, on pooling data for gastric visualization, only adequate versus inadequate was utilized and degrees of visualization beyond that was not assessed. Lastly, mortality was not assessed in the studies. Th is outcome would be particularly interesting but given the low mortality rate in UGIB, the studies did not have enough power to adequately assess this outcome.
In conclusion, erythromycin before endoscopy in patients with acute UGIB signifi cantly improves gastric mucosa visualization while reducing hospital stay and the need for a second-look endoscopy. Based on the evidence, pre-endoscopic administration of intravenous erythromycin in UGIB patients should be strongly considered with more guidelines being altered in the future to refl ect this strong evidence.
